Does AngioDynamics (ANGO) have what it takes to be a top stock pick for momentum investors? Let's find out.
The average of price targets set by Wall Street analysts indicates a potential upside of 63.2% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here is how AngioDynamics (ANGO) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
14 Jul 2025 (39 Days) Date | | - Cons. EPS | - EPS |
2 Apr 2025 Date | | - Cons. EPS | - EPS |
3 Jan 2025 Date | | - Cons. EPS | - EPS |
3 Oct 2024 Date | | - Cons. EPS | - EPS |
2 Oct 2024 Date | | - Cons. EPS | - EPS |
14 Jul 2025 (39 Days) Date | | - Cons. EPS | - EPS |
2 Apr 2025 Date | | - Cons. EPS | - EPS |
3 Jan 2025 Date | | - Cons. EPS | - EPS |
3 Oct 2024 Date | | - Cons. EPS | - EPS |
2 Oct 2024 Date | | - Cons. EPS | - EPS |
Medical - Instruments & Supplies Industry | Healthcare Sector | Mr. James C. Clemmer CEO | XSTU Exchange | US03475V1017 ISIN |
US Country | 748 Employees | - Last Dividend | - Last Split | 27 May 2004 IPO Date |
AngioDynamics, Inc. is a prominent provider of invasive medical devices, catering to the needs of professional healthcare providers across the United States and internationally. The company specializes in a broad spectrum of medical areas, including vascular access, surgery, peripheral vascular disease, and oncology. Established in 1988, AngioDynamics is committed to enhancing patient outcomes through its innovative technologies and solutions, headquartered in Latham, New York.